viewNemaura Medical Inc

Nemaura rises after supply deal for its SugarBEAT glucose monitor in Mideast

It’s a strategic move to crack open the wealthy markets of Saudi Arabia, Oman, Kuwait and Bahrain

Nemaura Medical Inc's sugarBEAT, a non-invasive continuous glucose monitoring device
The UK-based medtech company is eyeing explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by Europe and the Middle East

Nemaura Medical Inc (NASDAQ:NMRD) said Tuesday that it has inked an exclusive licensing and supply agreement for sugarBEAT, described as the world’s first painless non-invasive glucose monitor, with TPMENA. 

Saudi Arabia-headquartered TPMENA markets and sells medical devices in the Gulf Cooperation Council (GCC) Region, which includes the United Arab Emirates, Bahrain, Saudi Arabia, Oman, Qatar and Kuwait.

Investors reacted to the positive development and sent shares in the UK-based medtech company up nearly 4% to $1.06 on the New York Stock Exchange.

READ: Nemaura is a red hot medtech stock with a winner in its painless sugarBEAT glucose monitor

The GCC Region has more than 35 million diabetics, according to data from the International Diabetes Federation (IDF).

Specifically, in Saudi Arabia, 3.8 million adults are estimated to be living with diabetes, while 1.2 million adults are estimated to have diabetes in the United Arab Emirates.

“The GCC Region is a key market for SugarBEAT because the prevalence of diabetes is one of the highest in the world,” Nemaura Medical CEO Dr Faz Chowdhury said in a statement. “We are delighted to be involved with TPMENA, which brings an extensive network and proven track record.”

Latent demand 

The company said TPMENA has conducted extensive market research and received positive feedback from consumers and physicians.

“We look forward to accelerating the registration processes required for an aggressive GCC commercial launch of SugarBEAT upon receipt of CE Mark approval,” said Chowdhury.

SugarBEAT, which has been honed and perfected over seven years, is expected to receive the CE approval in the UK soon. The CE Mark is also required for sugarBEAT to launch commercially in the GCC region.

SugarBEAT, is a non-invasive continuous glucose monitoring device for use by persons with Type 1 and Type 2 diabetes, as well as for screening prediabetic patients.

Since sugarBEAT doesn’t require needles or insertion, it will challenge entrenched players like DexCom Inc (NASDAQ:DXCM), which markets the Dexcom G6 and Abbott Laboratories (NYSE:ABT) Libre System.

SugarBEAT consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five-minute intervals for periods of up to 24 hours. The innovation of sugarBEAT lies in its groundbreaking skin-patch technology, which allows for better glucose management.

A predecessor sugarBEAT device from Nemaura that resembled a wristwatch received CE Mark approval in 2016.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter@UttaraProactive 


Quick facts: Nemaura Medical Inc

Price: 4.6 USD

Market: NASDAQ
Market Cap: $105.38 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Nemaura Medical Inc named herein, including the promotion by the Company of Nemaura Medical Inc in any Content on the Site, the Company...


2 min read